RecruitingNCT04777916
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
A Prospective Non-interventional Study Documenting the Management and Outcomes of Adult Patients With Acute Myeloid Leukemia (AML)
Sponsor
Acute Leukemia French Association
Enrollment
5,000 participants
Start Date
Apr 14, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
During the last fifteen years, the landscape of AML diagnosis and therapeutical options has markedly evolved. Refined genetic and prognostic characterizations, together with new drug approvals and new allogeneic hematopoietic stem cell transplantation (HSCT) procedures, have increased patient journey diversity.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Patient aged 18 years old or more
- Patient with newly diagnosed previously untreated de novo, secondary or therapy-related AML
- Patients with R/R de novo, secondary or therapy-related AML
- Patient with Health insurance
Exclusion Criteria6
- Acute promyelocytic leukemia
- AML which is not morphologically proven (patients with granulocytic sarcoma may be included)
- For newly diagnosed AML: previous treatment of leukemia apart from hydroxyurea. Previous anti leukemia treatments are allowed if they were administered before the diagnosis of AML to treat a MDS, MPN, MPN/MDS or CML
- Patient weighting less than 50 kgs
- Opposition of the patient to participate to this non-interventional study
- More specific eligibility criteria might be requested to enter some study modules
Locations(30)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04777916
Related Trials
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT050924511 location
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT0700731229 locations
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
NCT019626361 location
Ivosidenib as Post-HSCT Maintenance for AML
NCT067074933 locations
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
NCT074519121 location